A rticular surface injury is a frequent problem, with recovery limited by incomplete natural healing mechanisms complicated by progression to osteoarthritis (OA), which leads to further pain and dysfunction.
Methods
A search was conducted through PubMed using various combinations of the terms stem cell, cell therapy, cell transplantation, cartilage, chondral, and chondrogenic to December 2013 with no earlier limit. Only 9 comparative studies (Table 1) were identified among a total of 45 human reports of local stem cell therapy for joint disorders (see the Appendix, available at http://sph.sagepub.com/content/suppl).
Three randomized trials, 102, 117, 119 3 nonrandomized cohort studies, 39, 61, 84 and 1 case-control study 64 compared stem cell with non-stem cell procedures. A further 2 cohort studies compared different stem cells or implantation methods. 69, 105 Statistical analysis was not performed because of differences in study populations and methods.
NoN-Cell-Based treatMeNt of ChoNdral INjury
Non-cell-based surgical treatment includes debridement, marrow stimulation by microfracture, abrasion or drilling of the subchondral bone plate, and osteochondral grafting (mosaicplasty). 55, 63, 83 Abnormal cartilage in defects produces detrimental effects on adjacent and opposing cartilage, and debridement can improve symptoms and potentially minimize further chondral loss. 28, 55 Activation of the innate repair mechanism by injuries involving the subchondral bone plate, as opposed to partial-thickness chondral injury, provides the rationale for marrow stimulation techniques where multiple small holes are placed in the subchondral bone of the defect. 55 The mechanism of action is thought to be due to the influx of chondroprogenitor cells. 63 
Cell-Based therapy
The first report describing ACI in humans was by Brittberg et al 10 in 1994, involving debridement, covering of the defect with a periosteal flap from the proximal medial tibia sutured to surrounding normal cartilage, and cultured chondrocyte injection beneath the periosteal flap.
Autologous chondrocyte implantation utilizes cultured, mature, autologous chondrocytes suspended in an injectable medium with newer variants using a collagen type I/III membrane (ACI-C, CACI, second generation) rather than periosteal cover (ACI-P, first generation). 11 Third generation techniques such as matrix-induced autologous chondrocyte implantation (MACI) use cells seeded onto the rough side of a collagen type I/III membrane with a smoother side facing the articular cavity, usually fixed with fibrin glue and sometimes sutures. 11 Characterized chondrocyte implantation (CCI) maximizes chondrogenic capacity through a controlled ex vivo process that produces clinically significant improvement with up to 4 years follow-up. 115 Comparing CCI with microfracture in a randomized trial, Saris et al 98, 99 found improved tissue regeneration, although similar clinical outcomes, at 1 year but improved clinical outcome for CCI at 3 years.
These procedures can result in improved clinical, arthroscopic, and histologic features, with hyaline-like cartilage or fibrocartilage present in 43.9% of ACI-C and 36.4% of MACI grafts in 1 prospective, randomized study by Bartlett et al. 4 In a randomized trial comparing ACI-P to MACI, Zeifang et al 128 found better Lysholm and Gillquist scores at 12 and 24 months in the ACI-P group but no significant difference in International Knee Documentation Committee (IKDC), Tegner Activity Score, or Short Form-36 scores.
In a systematic review of cell-based therapy for chondral lesions from 1994 to 2009, Nakamura et al 83 concluded that there was insufficient evidence to indicate superiority of cell-based therapy to non-cell-based treatments with relatively short-term follow-up and most studies demonstrating no convincing differences. Variable results have been obtained comparing ACI with microfracture, with some studies showing no significant difference and others suggesting superiority of ACI. 83 Second and third generation techniques offer potential advantages, but longer term follow-up is required.
11,83
Basad et al 5 demonstrated significantly improved Lysholm, Tegner, patient ICRS (International Cartilage Repair Society), and surgeon ICRS scores with MACI compared with microfracture at 2 years in a randomized study. For patients undergoing ACI after failed microfracture, significantly higher failure rates were observed. 91 The chondral defect site as well as level of sports activity and physical training may influence outcome. 83 Surgical technique and experience also play a role. Disadvantages of ACI/MACI include healthy cartilage damage at the donor site and lack of suitable donor cartilage in elderly patients with degenerative changes. 11, 83 steM Cell therapy
Sources of Stem Cells
The stem cells with the greatest capacity for differentiation are embryonic stem cells (ESCs). In addition to ethical concerns, questions of safety have arisen because of the risk of teratoma formation. 51 These concerns have prompted the search for alternative stem cell sources including adult cells and, more recently, induced pluripotential stem cells (iPSCs), although the teratoma risk currently persists with iPSCs. 51, 108 IPSCs from osteoarthritic cartilage undergo chondrogenic differentiation in vitro and show chondrogenesis after subcutaneous implantation in mice, but have not yet been used in in vivo articular surface repair. 126 Mesenchymal stem cells are multipotential cells originally isolated from bone marrow but naturally existing in many tissues, often around blood vessels. They are defined by the expression of various cell surface molecules (eg, CD73, CD90, CD105), the capacity for self-renewal, and the ability to differentiate into osteogenic, chondrogenic, or adipogenic lineages. 48, 93 While this capacity already signifies their applicability to musculoskeletal conditions, they also possess potent anti-inflammatory/immunosuppressive properties, 79 which may predict efficacy in OA. 48, 71 53 and placenta. 54 The potential therapeutic value for MSCs in the treatment of joint disorders is multifactorial, including paracrine effects on regenerating native tissue and immunomodulatory effects. 14, 48 The cytokine-based immunosuppressive properties of MSCs potentially induce immune tolerance, prompting investigation in multiple sclerosis, foreign graft rejection, and rheumatoid arthritis. 48, 95 These immunomodulatory effects may help slow the progression of OA by targeting the inflammatory processes in its pathogenesis. 79 So far, in the musculoskeletal system, MSCs derived from autologous bone marrow, subcutaneous adipose tissue, infrapatellar fat, and peripheral blood have been utilized in humans in treating osteochondral injury, OA, and rheumatoid arthritis. 64 93 Most animal and human stem cell studies for cartilage repair used BM-MSCs. Initial human reports employed culture-expanded BM-MSCs, 119 but subsequent publications utilized bone marrow concentrate (BMC) without expansion, allowing a same-day procedure. 15, 38 BMC contains nucleated cells with a small stem cell component derived from marrow aspirates after removal of most red cells and plasma by centrifugation. 38 Both show benefits compared with controls in small, human studies. 39, 84, 117, 119, 123 Technique-related differences in aspirate yields include site (anterior vs posterior iliac crest) and syringe size. 92 Substantial variability also exists for MSC counts between patients. 92 For these reasons, comparison between studies or patients within a study is difficult unless the sample is analyzed prior to implantation. Although cell numbers may be counted, characterization with surface markers is required to assess true stem cell counts. 18, 105 Reported transplanted BM-MSC counts range from 8 million 25 to 45.6 million 17 cells. Outcome for femoral head osteonecrosis and tibial nonunion is proportionate to the number of transplanted progenitor cells. 49, 50 This remains to be shown in humans for cartilage, but the principle of improved healing with greater cell numbers is important. In vitro work shows that increasing initial seeding density of BM-MSC enhances chondrogenesis. 52 Government regulation forms a barrier to using culture-expanded cells in some countries, including the United States, as the degree of ex vivo manipulation classifies the treatment in the same manner as a drug. 20 Geographic locations of human studies are listed (see the Appendix, available at http://sph.sagepub.com/content/ suppl). The US Food and Drug Administration has currently not approved any stem cell products for use in the United States other than cord blood-derived hematopoietic stem cells for certain indications. 114 While the use of culture-expanded cells is prohibited, some clinics offer same day procedures using minimally manipulated cells such as BMC, concentrated at the point of care. 20 The issue of stem cell regulation continues to be a subject of active debate.
An apparent disadvantage of BM-MSCs is that cell numbers diminish with age and exhibit reduced proliferative capacity and increased rates of apoptosis compared with BM-MSC from younger patients. 106 
Adipose-Derived Stem Cells and Stromal Vascular Fraction
Mesenchymal stem cells in adipose tissue arise from or form perivascular cells. 13, 130, 131 Adipose tissue contains proportionally higher numbers of MSCs (approximately 10% of nucleated cells) than bone marrow and is amenable to liposuction without significant morbidity. In contrast to BM-MSCs, numbers do not decline with age but do decline with obesity. 3 Stem cells may differ in numbers from abdominal adipose tissue compared with the hip or thigh, but proliferation and differentiation do not appear influenced by harvest site. 56 As with bone marrow, adipose stem cells may be utilized in 2 major forms. Stromal vascular fraction (SVF) is a heterogeneous population of cells that may contain MSCs, fibroblasts, endothelial cells, leukocytes (lymphocytes and macrophages), and pericytes. 8 Stem cells from SVF may be separated and expanded in vitro (adipose-derived stem cells [ADSCs] ).
An advantage of SVF and BMC is elimination of the time lag between harvest and implantation, minimizing exposure to risks, reducing cost and logistical difficulties. 39, 88, 95 However, the lack of cellular content identification of SVF is a major problem in evaluating clinical efficacy and patient responses. SVF contains large numbers of T regulatory (Treg) cells that may assist in immunosuppression and tolerance induction. 95 Intra-articular SVF has been successfully utilized in dogs with elbow or hip OA but with suboptimal results in horses. 8, 9, 35 Co-administration of non-infrapatellar fat-derived SVF showed superior clinical results at mean 21.8-month follow-up compared with non-MSC controls in a human study. 61 Improved cartilage repair was seen with culture-expanded ADSCs compared with controls in rabbit full-thickness chondral defects with better integration and more hyaline cartilage formation, but their use in humans has not been reported. 31 
Infrapatellar Fat Pad-Derived Stem Cells
Infrapatellar fat differs in composition to subcutaneous adipose tissue, containing a large amount of collagenous tissue and possibly synoviocytes. 127 While exhibiting characteristics of ADSCs, 57 they have more similarities with fibrous synoviumderived cells than subcutaneous fat-derived cells, and possibly greater chondrogenic potential. 78 In rabbits, cells cultured from infrapatellar fat showed promising results compared with controls. 110 Infrapatellar SVF (not culture-expanded) has shown similar clinical findings in humans at 1 year compared with MSC free controls undergoing arthroscopic debridement, implying a potential benefit from MSC because of poorer preoperative clinical scores and ICRS grades. 64 
Peripheral Blood Mesenchymal Stem Cells/Progenitor Cells
Peripheral blood presents another source of MSCs, obtained with relative ease and no significant donor site morbidity. 21 MSCs derived from human peripheral blood cells (PBSCs) exhibit similar in vitro chondrogenic potential to BM-MSCs, although they are far less concentrated in blood than in marrow. 23 Use of granulocyte-colony stimulating factor (G-CSF) increases MSC numbers in peripheral blood. 21, 101 While generally well tolerated, rare risks of G-CSF in healthy donors include splenic rupture and adult respiratory distress syndrome, although the theoretical risk of hematologic malignancy remains to be proven in the healthy donor population. 32 Following an initial pilot report, 101 PBSCs have been assessed in a randomized study augmenting arthroscopic subchondral drilling with postprocedural injections of either PBSC and hyaluronic acid (HA) or HA alone, reporting improved histologic and MRI scores at 18 months but no significant clinical difference at 24 months. 102 Other stem cell sources trialed in animals, but not humans, include periosteum, synovium, and skeletal muscle.
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Methods of steM Cell traNsplaNtatIoN
Open Surgical Implantation of MSCs
Surgical implantation may be similar to ACI, with MSCs beneath a periosteal 119 or collagen 43 cover instead of cultured chondrocytes. 45, 60, 67, 74, 84, 103, 104, 109, [119] [120] [121] [122] [123] A cell-seeded construct (analogous to MACI) may be used rather than suspended cells. 11 An ideal scaffold is nontoxic, absorbable, mechanically sound, and promotes cell growth. 46 Wakitani et al 118 found that osteochondral progenitor cells from bone marrow or periosteum in type I collagen gel produced superior repair of full-thickness rabbit medial femoral condylar defects compared with empty defects or a cell-free collagen gel with hyaline cartilage formation and mechanically superior repair tissue. Macroscopic appearance at 24 weeks and histologic appearance at 12 and 24 weeks was less favorable than at 4 weeks postimplantation. 118 Wakitani et al 119 used culture-expanded BM-MSCs in collagen gel in medial femoral condylar defects of humans with OA at the time of high tibial osteotomy, with 12 patients randomized to each group. Subchondral abrasion was performed to facilitate bleeding. A BM-MSC-collagen gel sheet composite was applied to the defect and covered with autologous periosteum. The control group received the same treatment without BM-MSCs.
BM-MSC patients demonstrated improved arthroscopic and histologic scores 28 to 95 weeks following treatment, with no clinical difference, including on repeat assessment at 64 months. 119, 123 Gobbi et al 43 Arthroscopic evaluation in 4 knees was normal to nearly normal, and histology in 3 patients showed hyaline-like features. 43 Skowroński and Rutka 105 showed significantly better KOOS, Lysholm, and VAS scores for PBSC over nonexpanded BMC in conjunction with autologous iliac bone grafting of medial femoral condylar osteochondral lesions at 6 months and 1 year, but commented that it could reflect double the transplanted cell numbers compared with the BMC group, with possible contribution from more stem cells provided by marrow stimulation in the G-CSF-treated PBSC group.
Regarding open foot and ankle chondral defect repairs, implantation of nonexpanded BMC-impregnated collagen matrix was reported by Richter and Zech 94 in 25 patients who were followed up with at 2 years with significant improvements in VAS foot and ankle scores.
Arthroscopic Implantation of Stem Cells
Giannini et al 38, 40 followed 49 patients, aged 14 to 50 years, for 4 years after 1-step arthroscopic implantation of nonexpanded BMC for talar osteochondral lesions, with either collagen powder/platelet gel or HA membrane/platelet gel scaffolds. American Orthopaedic Foot and Ankle Society (AOFAS) scores improved, with best results at 24 months, but deteriorating at 36 and 48 months.
Stem Cell Versus Autologous Chondrocyte Implantation
Few studies directly compare stem cell treatment to ACI. Adachi et al 1 showed similar results of B-galactosidase gene-transfected muscle-derived stem cells (MDSCs) with similarly transfected chondrocytes in rabbits. Testing a gellan gum hydrogel in rabbits, Oliveira et al 86 noted improved hyaline cartilage formation with chondrogenically predifferentiated ADSCs compared with chondrocytes, but similar results between undifferentiated ADSCs and chondrocytes.
Autologous, cultured BM-MSCs were compared with matrixassociated autologous chondrocyte transplantation in sheep, both suspended in collagen gel, with superior results for BM-MSCs at 1 year, particularly regarding integration with adjacent native cartilage. 72 Arthroscopic, nonexpanded BMC implantation was retrospectively compared with open field and arthroscopic ACI. 39 Significant clinical improvement was found in all 3 groups at 36 months, with no significant difference between them. Second-look arthroscopies demonstrated intact cartilage in all cases, with components of hyaline cartilage at biopsy. The 1-step arthroscopic BMC technique was less than half the cost of the 2-step arthroscopic ACI technique. 39 Nejadnik et al 84 matched 36 patients undergoing ACI-P with 36 patients receiving autologous, culture-expanded BM-MSCs, with cultured chondrocytes or BM-MSCs implanted beneath a sutured periosteal patch in similar techniques. No significant difference was shown between the 2 groups in terms of clinical outcome up to 24 months except for physical role functioning, which was better improved for the BM-MSC group. The BM-MSC therapy required only 1 surgery, reduced costs, and caused less donor site morbidity. In contrast to the ACI group, an agerelated response was not evident with BM-MSCs. 84 
Intra-Articular Injection of MSCs Rationale
Intra-articular injection holds several potential advantages, including reduced recovery time and less cost. 15, 25, 33, 58, 64, 101 Same day intra-articular administration of cells surgically obtained from the infrapatellar fat pad has been used to augment arthroscopic debridement. 64 From a therapeutic perspective, intra-articular injection may be better matched to the pathogenesis of OA, 79, 100 although it may increase the risk of synovial proliferation. 63 
Cartilage Defects
In animal studies involving surgically created injuries to anterior cruciate ligaments, menisci, and articular cartilage, intraarticularly administered labeled BM-MSCs migrated to sites of injury. 68, 80, 81 To enhance migration to the desired location, Kobayashi et al 62 utilized an external magnetic force to direct magnetically labeled, intra-articularly injected BM-MSCs to experimentally created osteochondral defects in rabbit and swine patellae. In a further laboratory study, the magnetic force improved cell adhesion with no deleterious effects on cell proliferation for up to 3 weeks. 82 
Osteoarthritis
The anti-inflammatory and immunomodulatory effects of MSCs may retard the progression of OA. Intra-articular injections of stem cells slowed progression of surgically induced OA in goats following a single intra-articular dose of cultured BM-MSCs, 81 in rabbits using infrapatellar fat pad-derived MSCs, 110 and in rats using MDSCs with transduced genes. 73 BM-MSCs may also prevent the onset of posttraumatic OA in mice when injected at the same time as experimentally created closed tibial plateau fracture. 30 Studies of animals with spontaneous OA, as well as experimental OA, have also reported improvement following MSC injection. 8, 9, 44, 100 Cell labeling shows incorporation into damaged cartilage and partial cartilage regeneration in guinea pigs using cultured human BM-MSCs. 100 Black et al 8 reported
significant clinical improvement in dogs with spontaneous OA of the coxofemoral joint following intra-articular SVF compared with placebo in a randomized, double-blinded, placebocontrolled trial. Improvements were also noted following a single humeroradial SVF injection for dogs with elbow OA, although with no control group in this study. 9 Guercio et al 44 found improved clinical benefit following ADSC injection in 4 dogs with lameness due humeroradial OA that had previously failed to respond to anti-inflammatory drugs. While most investigations appear to focus on restoration of articular cartilage, stem cell therapy may also benefit meniscal defects in animals and humans. 17, 81 Orozco et al 87 followed 12 patients receiving intra-articular, autologous-expanded BM-MSCs (40 × 10 6 cells) for 1 year, demonstrating significantly improved VAS, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Lequesne scores, with no significant difference in SF-36 and reduction in pain occurring within 3 months. Decreased poor quality cartilage on T2 mapping was seen in 11 patients. No human studies have yet compared MSC injection with other treatments in the absence of concurrent surgery.
Augmenting Surgery
Mesenchymal stem cell injection has been utilized as an adjunct to surgical techniques in humans 64, 69, 101 and animals. 75, 107 In goats, BM-MSCs in alginate applied between osteochondral plugs during mosaicplasty was superior at 24 weeks compared with mosaicplasty alone, and better still using transforming growth factor-β1-transduced BM-MSCs. 107 Comparing intra-articular BM-MSCs and HA to intra-articular HA alone following microfracture of full-thickness chondral defects in horses, McIlwraith et al 75 noted significantly increased firmness and a nonsignificant trend for better overall repair quality with BM-MSCs.
The location of the infrapatellar fat pad makes it an attractive harvest target. Koh and Choi 64 utilized intra-articular injection of nonexpanded infrapatellar fat cells combined with arthroscopic debridement and PRP in humans with knee OA, with similar 1-year clinical findings compared with controls receiving only PRP post-debridement but significantly worse preoperative clinical (Tegner, Lysholm, and VAS) scores and ICRS grades in the MSC group, favoring a benefit from MSC injection. Of the 25 MSC patients, 18 were reassessed at 2 years, with significantly improved clinical features (WOMAC, Lysholm, and VAS scores) as well as MRI scores compared with preoperative, including significant clinical improvement in patients with grade 3 compared with grade 4 OA. 65 The fat pad was acquired at surgery, but the 3-to 4-hour processing necessitated a separate procedure that day. 64 Kim et al 61 used non-expanded buttock adipose cells (SVF) as an intra-articular supplement to arthroscopic debridement and microfracture of talar osteochondral lesions. Significantly better clinical scores were obtained with MSC (31 ankles) compared with arthroscopic surgery alone (37 ankles).
In a randomized trial, Varma et al 117 compared 25 patients with mild to moderate knee OA undergoing arthroscopic debridement alone with 25 patients undergoing arthroscopic debridement followed by intra-articular, nonexpanded BMC injection. Significant improvements in activities of daily living, sports and recreational activity, and quality of life scores were seen at 6 months. 117 Saw et al 102 randomized 50 patients with ICRS grade 3-4 chondral defects undergoing arthroscopic debridement and subchondral drilling to a series of 8 injections of either non-expanded PBSC and HA or HA alone. Significantly better histologic scores (1066 vs 957) and MRI scores (9.9 vs 8.5) were reported at 18 months, with blinding of the reporting radiologist and pathologist, although no significant difference in IKDC scores at 24 months (74.8 vs 71.1). 102 Lee et al 69 compared 35 knee full-thickness chondral defects undergoing arthroscopic debridement and microfracture, followed by outpatient injection of culture-expanded BM-MSC and HA, with 35 matched patients receiving open implantation of BM-MSC sheets beneath a sutured periosteal cover. Both groups showed significantly improved IKDC, Lysholm, VAS, and SF-36 scores at up to 2 years. The arthroscopic-injected group experienced more improvement in IKDC and Lysholm scores compared with the open group but similar improvement in VAS and SF-36 scores. MRI at 1 year showed good defect filling and integration. 69 Growth faCtors, platelet-rICh plasMa, GeNe therapy, aNd hyaluroNIC aCId Platelet-rich plasma (PRP) is a source of autologous growth factors and an effective treatment for elbow tendinopathy. 24 A systematic review of intra-articular PRP injection for cartilage repair has shown safety in humans with potential pain reduction and improved function. 36 Longer term follow-up is required before it can be recommended for OA therapy. 36 After chemical induction of OA in rat knee joints, Mifune et al 76 compared MDSCs expressing bone morphogenetic protein 4 (BMP-4) and sFlt-1 with and without PRP. Improved articular cartilage repair was seen at 4 and 12 weeks with the addition of PRP.
Hyaluronic acid, a glycosaminoglycan extracellular matrix constituent, has been used for human OA with MRI evaluation up to 24 months showing beneficial effects on cartilage preservation. 125 Multiple animal studies have shown the combined use of stem cells and HA to produce better results than HA alone. 68, 75, 79, 81 Following in vitro expansion, stem cells may be induced via transforming growth factor-β1 or BMP-2 to undergo chondrogenic differentiation 22, 72 or can be uninduced. 93, 129 Encouraging results have been achieved with both approaches compared with controls. 22, 129 Comparing induced with uninduced cells in animal studies shows mixed results. 22, 72 safety of MeseNChyMal steM Cellrelated proCedures
In vitro manipulation creates the opportunity for infection, necessitating antibiotic administration above the minimum inhibitory concentration for relevant organisms while not impeding MSC proliferation and differentiation. 59 Malignancy has been flagged as a potential risk of MSC implantation but has not yet been shown in clinical practice. 18, 19, 123 Miura et al 77 found that fibrosarcoma developed from murine BM-MSCs after numerous in vitro passages. Tolar et al 111 also identified sarcomatous transformation from mouse BM-MSCs expanded in vitro.
In 2005, Rubio et al 97 reported that after long-term in vitro culture of 4 to 5 months, human ADSCs exhibited malignant transformation. The group retracted this article in 2010, unable to reproduce the findings, proposing potential crosscontamination. 29 Another group described spontaneous transformation of BM-MSCs due to cross-contamination by immortalized cell lines, emphasizing the need for DNA fingerprinting. 96, 112 Bernardo et al 7 found that human BM-MSCs did not demonstrate malignant transformation after long-term culture, showing telomeric shortening with progressive decline in proliferation until reaching senescence.
dIsCussIoN
Cell therapy represents promising treatment for many conditions, including joint disorders. The most widely practiced form, ACI and its newer variants, is capable of promoting cartilage repair and providing clinical benefit, although there is insufficient evidence to recommend these procedures over marrow stimulation techniques and osteochondral grafting. 83 Only limited human data exist for use of MSCs, but both surgical implantation and intra-articular injection appear to be safe and exhibit reasonable efficacy. There is currently a paucity of randomized human trials.
Cell sources that do not require in vitro expansion, such as BMC or SVF, provide the opportunity for same day therapy by reducing the turnaround time from cell harvest to treatment. 38, 64 Intra-articular injection offers a reduction in postoperative recovery time. 8, 64, 117 For chondral injury, MSC therapy may improve symptom control through anti-inflammatory and immunomodulatory effects. 19 
CoNClusIoN
At present, there is no conclusive evidence to recommend cell therapy over non-cell-based procedures, but both treatments appear to offer beneficial results. Non-stem cell therapy such as ACI, mosaicplasty, and microfracture at present possesses more clinical evidence than MSC treatments. 
